Merck Income from Continuous Operations 2010-2024 | MKKGY
Merck annual/quarterly income from continuous operations history and growth rate from 2010 to 2024. Income from continuous operations can be defined as a company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change
- Merck income from continuous operations for the quarter ending June 30, 2024 was $0.652B, a 15.37% decline year-over-year.
- Merck income from continuous operations for the twelve months ending June 30, 2024 was $2.849B, a 11.75% decline year-over-year.
- Merck annual income from continuous operations for 2023 was $3.067B, a 12.81% decline from 2022.
- Merck annual income from continuous operations for 2022 was $3.518B, a 2.98% decline from 2021.
- Merck annual income from continuous operations for 2021 was $3.626B, a 59.2% increase from 2020.
Merck Annual Income from Continuous Operations
(Millions of US $) |
| 2023 |
$3,067 |
| 2022 |
$3,518 |
| 2021 |
$3,626 |
| 2020 |
$2,278 |
| 2019 |
$1,452 |
| 2018 |
$1,291 |
| 2017 |
$2,950 |
| 2016 |
$1,807 |
| 2015 |
$1,241 |
| 2014 |
$2,240 |
| 2013 |
$2,535 |
| 2012 |
$2,125 |
| 2011 |
$1,948 |
| 2010 |
$839 |
| 2009 |
$536 |
Merck Quarterly Income from Continuous Operations
(Millions of US $) |
| 2024-06-30 |
$652 |
| 2024-03-31 |
$759 |
| 2023-12-31 |
$633 |
| 2023-09-30 |
$805 |
| 2023-06-30 |
$770 |
| 2023-03-31 |
$859 |
| 2022-12-31 |
$667 |
| 2022-09-30 |
$933 |
| 2022-06-30 |
$926 |
| 2022-03-31 |
$992 |
| 2021-12-31 |
$923 |
| 2021-09-30 |
$901 |
| 2021-06-30 |
$900 |
| 2021-03-31 |
$902 |
| 2020-12-31 |
$512 |
| 2020-09-30 |
$942 |
| 2020-06-30 |
$318 |
| 2020-03-31 |
$505 |
| 2019-12-31 |
$375 |
| 2019-09-30 |
$377 |
| 2019-06-30 |
$473 |
| 2019-03-31 |
$226 |
| 2018-12-31 |
$204 |
| 2018-09-30 |
$376 |
| 2018-06-30 |
$291 |
| 2018-03-31 |
$420 |
| 2017-12-31 |
$1,165 |
| 2017-09-30 |
$763 |
| 2017-06-30 |
$465 |
| 2017-03-31 |
$557 |
| 2016-12-31 |
$285 |
| 2016-09-30 |
$513 |
| 2016-06-30 |
$355 |
| 2016-03-31 |
$654 |
| 2015-12-31 |
$138 |
| 2015-09-30 |
$407 |
| 2015-06-30 |
$380 |
| 2015-03-31 |
$321 |
| 2014-12-31 |
$313 |
| 2014-09-30 |
$331 |
| 2014-06-30 |
$405 |
| 2014-03-31 |
$446 |
| 2013-12-31 |
$382 |
| 2013-09-30 |
$450 |
| 2013-06-30 |
$419 |
| 2013-03-31 |
$345 |
| 2012-12-31 |
$350 |
| 2012-09-30 |
$232 |
| 2012-06-30 |
$-78 |
| 2012-03-31 |
$222 |
| 2011-12-31 |
$178 |
| 2011-09-30 |
$321 |
| 2011-06-30 |
$-124 |
| 2011-03-31 |
$466 |
| 2010-12-31 |
$89 |
| 2010-09-30 |
$272 |
| 2010-06-30 |
$224 |
| 2010-03-31 |
$255 |
| 2009-12-31 |
$107 |
| 2009-09-30 |
$206 |
| 2009-06-30 |
$148 |
| 2009-03-31 |
$75 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-DRUGS |
$21.306B |
$22.719B |
|
Merck is a global pharmaceutical and chemical company. Its success is characterized by innovations from entrepreneurial employees. Merck's operating activities come under the umbrella of Merck KGaA, in which the Merck family holds an approximately 70% interest and free shareholders own the remaining approximately 30%. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been an independent company ever since.
|
